Three New Lanostanoids from the Mushroom *Ganoderma tropicum*

Shuang-Shuang Zhang 1, Yu-Guang Wang 2, Qing-Yun Ma 2, Sheng-Zhuo Huang 2, Li-Li Hu 2, Hao-Fu Dai 2, Zhi-Fang Yu 1,∗ and You-Xing Zhao 2,∗

1 College of Food Science and Technology, Nanjing Agricultural University, Nanjing 210095, China; E-Mail: 2012208021@njau.edu.cn
2 Key Laboratory of Biology and Genetic Resources of Tropical Crops, Institute of Tropical Bioscience and Biotechnology, Chinese Academy of Tropical Agricultural Sciences, Haikou 571101, China; E-Mails: wangyuguang@itbb.org.cn (Y.-G.W.);
maqingyun@itbb.org.cn (Q.-Y.M.); huangshengzhuo@itbb.org.cn (S.-Z.H.);
lili861025@aliyun.com (L.-L.H.); daihaofo@itbb.org.cn (H.-F.D.)

* Authors to whom correspondence should be addressed; E-Mails: yuzhifang@njau.edu.cn (Z.-F.Y.);
zhaoyouxing@itbb.org.cn (Y.-X.Z.); Tel./Fax: +86-25-8439-9098 (Z.-F.Y.);
+86-898-6698-9095 (Y.-X.Z.).

Academic Editor: Derek J. McPhee

Received: 19 December 2014 / Accepted: 5 February 2015 / Published: 16 February 2015

**Abstract:** Three new lanostanoid triterpenes—ganotropic acid (1), 3β,7β,15α,24-tetrahydroxy-11,23-dioxo-lanost-8-en-26-oic acid (2) and 3β,7β,15α,28-tetrahydroxy-11,23-dioxo-lanost-8,16-dien-26-oic acid (3)—were isolated from the *n*-BuOH extract of the fruiting bodies of the mushroom *Ganoderma tropicum*. Their structures were elucidated by 1D and 2D NMR spectroscopy, as well as HR-EI-MS data.

**Keywords:** Ganodermataceae; *Ganoderma tropicum*; lanostanoid triterpenes

1. Introduction

*Ganoderma*, the major genus in the family Ganodermataceae, are widely used to cure various chronic diseases such as hypertension, diabetes, hepatitis and cancers [1–3]. Among them some species are used as valuable Traditional Chinese Medicines (TCM). Phytochemical investigations on some *Ganoderma*
species showed that ganoderma triterpenes (GTs) are mainly lanostanoid-type triterpenes with extensive biological and pharmacological activities, including cytotoxic [4,5], hepatoprotective [6,7], anti-inflammatory [8,9], and antioxidant [10] properties. *Ganoderma tropicum* is a main wild *Ganoderma* mushroom species found distributed in tropical areas of China. It is used as a health supplement and folk medicine alternative to *Ganoderma lucidum* and *Ganoderma sinensis* which are recorded in the Chinese Pharmacopeia to treat coronary heart disease and chronic hepatitis [11].

Acetylcholinesterase (AChE) inhibitors [12] have been considered promising tools to treat progressive degenerative neurologic disorders (Alzheimer disease and Parkinson's disease [13,14]). Previously, we have reported four new lanostanoids from the EtOAc extract of the fruit bodies of *G. tropicum*, among which 3β,7β,15β-trihydroxy-11,23-dioxolanost-8,16-dien-26-oic acid methyl ester showed AChE inhibitory activity [15,16]. In continuation of those studies, three new lanostanoids—ganotrophic acid (1), 3β,7β,15α,24-tetrahydroxy-11,23-dioxolanost-8-en-26-oic acid (2) and 3β,7β,15α,28-tetrahydroxy-11,23-dioxolanost-8,16-dien-26-oic acid (3) (Figure 1) have been obtained from the n-BuOH extract of the fruit bodies of this fungus. In this paper, we describe the isolation, structural elucidation, and assay of AChE inhibitory activity of these new compounds.

![Figure 1. Structures of compounds 1–3.](image-url)

2. Results and Discussion

Compound 1 was obtained as a white power, and its molecular formula was assigned to be C₃₀H₄₄O₇, with nine degrees of unsaturation, from its HREIMS (m/z 516.3095 [M]+). The IR spectrum revealed the presence of hydroxyl (3743 and 3442 cm⁻¹), carbonyl (1768 cm⁻¹) and double bond (1652 cm⁻¹) absorptions. The ¹H-NMR spectrum (Table 1) of compound 1 exhibited signals of seven methyls (δH 0.84 (3H, s, H-29), 1.01 (3H, d, J = 6.9 Hz, H-21), 1.02 (3H, s, H-28), 1.14 (3H, s, H-18), 1.24 (3H, s, H-19), 1.26 (3H, d, J = 7.2 Hz, H-27), 1.32 (3H, s, H-30)). The ¹³C-NMR and DEPT spectroscopic data (Table 2) showed 30 carbon resonances, including seven methyls, seven methylenes, six methines (three oxygenated), and ten quaternary carbons (two olefinic, two carbonyl, and two oxygenated), suggesting a triterpenoid skeleton. Further comprehensive analysis of the 1D and 2D NMR spectra indicated that compound 1 had the lanostane skeleton as ganoderic acid C₂ [17]. However, the ¹³C-NMR data for compound 1 had two oxygenated quaternary carbons (C-23 and C-17) instead of the corresponding carbonyl (C-23) and methyl (C-17) in ganoderic acid C₂. Apart from seven degrees of unsaturation (four rings, two carbonyls and one double bond), the remaining elements of the unsaturation in compound 1 were assumed to be two rings in the side chain. These were reminiscent of the presence of two oxygenic five-membered rings in compound 1 with the characteristic C-23 spiro carbon (δc 113.4) similar to that of abietospiran [18]. This partial structure was supported by HMBC correlations of H-27 with C-24.
(δC 44.8) and C-26 (δC 179.2), H-24 and H-22 with C-23 as well as H-21 with C-17 (δC 94.9) and C-22 (δC 44.7) (Figure 2). The stereo-configuration of the lanostane skeleton for compound 1 was determined based on ROESY spectroscopic data and comparison of the NMR data with those similar structures. The NOE correlations of H-3/H-5, H-3/Me-28, H-7/H-5, H-7/Me-30 and H-15/Me-18 in the ROESY experiment indicated that 3-OH and 7-OH were β-oriented and 15-OH was α-oriented.

Table 1. 1H-NMR (500 MHz) spectroscopic data (δH in ppm, J in Hz) of compounds 1 (in CDCl3) and 2, 3 (in CD3OD).

| H     | 1     | 2     | 3     |
|-------|-------|-------|-------|
| 1α    | 2.75 m| 2.71 m| 2.79 m|
| 1β    | 0.92 m| 0.94 m| 0.97 m|
| 2α    | 2.08 m| 2.18 m| 2.01 m|
| 2β    | 1.64 m| 1.63 m| 1.67 m|
| 3α    | 3.21 dd (J = 5.2, 11.0) | 3.15 dd (J = 4.8,11.8) | 3.60 dd (J = 5.0,11.8) |
| 5α    | 0.89 d (J = 4.5) | 0.95 d (J = 3.0) | 1.40 d (J=12.5) |
| 5β    | 2.10 m| 2.30 m| 2.03 m|
| 7α    | 4.59 dd (J = 7.2, 10.4) | 4.53 dd (J = 7.4, 10.5) | 4.56 dd (J = 7.3, 10.0) |
| 12α   | 3.11 d (J = 15.6) | 2.87 d (J = 15.2) | 3.00 d (J = 14.4) |
| 12β   | 2.25 d (J = 15.6) | 2.41 d (J = 15.2) | 2.75 d (J = 14.4) |
| 15β   | 4.80 dd (J = 8.1, 8.6) | 4.77 dd (J = 7.2, 9.3) | 5.42 s |
| 16α   | 2.40 dd (J = 8.1, 15.0) | 1.81 m | 5.25 s |
| 16β   | 2.30 m|       |       |
| 17α   |       | 1.93 m|       |
| 18    | 1.14 s| 0.98 s| 1.01 s|
| 19    | 1.24 s| 1.25 s| 1.26 s|
| 20    | 2.28 m| 2.05 m| 2.63 m|
| 21    | 1.01 d (J = 6.9) | 0.89 d (J = 6.4) | 1.03 d (J = 6.8) |
| 22    | 1.83 d (J = 14.0, α-H) | 2.60 m | 2.53 m|
|       | 2.70 dd (J = 6.7, 14.0, β-H) | 2.50 m | 2.30 m|
| 24    | 2.48 dd (J = 8.1, 12.8, α-H) | 4.39 d (J = 5.0) | 2.85 m|
| 25    | 2.94 m| 2.88 m| 2.86 m|
| 27    | 1.26 d (J = 7.2) | 1.09 d (J = 7.1) | 1.15 d (J = 7.0) |
| 28    | 1.02 s| 1.02 s| 3.53 d (J = 11.2) |
| 29    | 0.84 s| 0.84 s| 0.72 s|
| 30    | 1.32 s| 1.26 s| 1.28 s|

Figure 2. Selected HMBC (H→C) correlations of compounds 1–3.
Table 2. $^{13}$C-NMR (125 MHz) spectroscopic data ($\delta_C$ in ppm) of compounds 1 (in CDCl$_3$) and 2, 3 (in CD$_3$OD).

|   | 1     | 2     | 3     |
|---|-------|-------|-------|
| 1 | 34.7 (t) | 35.9 (t) | 35.4 (t) |
| 2 | 27.9 (t) | 28.8 (t) | 28.0 (t) |
| 3 | 78.4 (d) | 73.2 (d) | 72.4 (d) |
| 4 | 38.8 (s) | 39.7 (s) | 43.3 (s) |
| 5 | 49.1 (d) | 50.4 (d) | 52.9 (d) |
| 6 | 27.7 (t) | 29.0 (t) | 28.5 (t) |
| 7 | 69.2 (d) | 70.1 (d) | 69.7 (d) |
| 8 | 158.8 (s) | 161.3 (s) | 162.3 (s) |
| 9 | 141.9 (s) | 143.5 (s) | 142.7 (s) |
| 10 | 38.7 (s) | 39.7 (s) | 39.8 (s) |
| 11 | 200.2 (s) | 202.3 (s) | 201.9 (s) |
| 12 | 47.2 (t) | 53.2 (t) | 48.5 (t) |
| 13 | 49.7 (s) | 48.4 (s) | 53.0 (s) |
| 14 | 54.5 (s) | 55.3 (s) | 57.6 (s) |
| 15 | 73.2 (d) | 78.9 (d) | 78.1 (d) |
| 16 | 45.0 (t) | 37.1 (t) | 125.6 (d) |
| 17 | 94.9 (s) | 49.0 (d) | 155.9 (s) |
| 18 | 19.9 (q) | 19.8 (q) | 20.7 (q) |
| 19 | 19.5 (q) | 17.5 (q) | 20.0 (q) |
| 20 | 44.0 (d) | 33.3 (d) | 28.6 (d) |
| 21 | 18.3 (q) | 20.2 (q) | 22.7 (q) |
| 22 | 44.7 (t) | 46.7 (t) | 49.5 (t) |
| 23 | 113.4 (s) | 212.9 (s) | 209.9 (s) |
| 24 | 44.8 (t) | 78.9 (d) | 47.4 (d) |
| 25 | 35.7 (d) | 43.2 (d) | 35.9 (d) |
| 26 | 179.2 (s) | 177.6 (s) | 179.6 (s) |
| 27 | 15.1 (q) | 11.4 (q) | 17.5 (q) |
| 28 | 28.3 (q) | 28.7 (q) | 66.2 (t) |
| 29 | 15.8 (q) | 16.4 (q) | 13.0 (q) |
| 30 | 21.4 (q) | 20.0 (q) | 23.3 (q) |

The stereoconfigurations of chiral carbons C-17, C-20 and C-23 in the oxygenated five-membered ring in the side chain were determined to be the same as in abietospiran from their similar NMR data. The $\alpha$-orientation of Me-27 was deduced based on analysis of ROESY correlations of H-24$\alpha$ ($\delta_H$ 2.48 dd (J = 8.1, 12.8)) with Me-21 and Me-27. Therefore, compound 1 was identified as (23S,25R)-3$\beta$,7$\beta$,15$\alpha$-trihydroxy-11-oxo-17,23-epoxy lanost-8-en-26,23-olide, named ganotropic acid.

Compound 2 had a molecular formula C$_{30}$H$_{46}$O$_8$ as established by its HREIMS (m/z 534.3202 [M$^+$]), as well as its $^{13}$C NMR and DEPT spectroscopic data (Table 2) revealing 30 carbon resonances. Detailed analysis of its $^{13}$C-NMR spectra showed that compound 2 was highly similar to ganoderic acid C$_2$, suggesting a lanostane skeleton. The only difference was the existence of the hydroxymethine signal $\delta_C$ 78.9 at C-24 in 2 instead of a methylene group in ganoderic acid C$_2$. The hydroxymethine was assigned to be at C-24 based on the HMBC correlations of H-24 ($\delta_H$ 4.39 d (J = 5.0)) with C-26 ($\delta_C$ 177.6) and
Compound 2 had the same basic lanostane configuration as that of ganoderic acid C2. The β-orientations of 3-OH and 7-OH were determined by ROESY correlations of H-3 [δH 3.15 dd (J = 4.8, 11.8)] with H-5, and H-7 [δH 4.53 dd (J = 7.4, 10.0)] with Me-28. The α-orientation of 15-OH was assigned from ROESY correlation of H-15 [δH 4.77 dd (J = 7.2, 9.3)] with Me-18. Based on above evidence, compound 2 was elucidated as 3β,7β,15α,24-tetrahydroxy-11,23-dioxo-lanost-8-en-26-oic acid.

Compound 3 was assigned the molecular formula C30H44O8 by analyses of its HREIMS (m/z 532.3030 [M]+) and 13C-NMR spectroscopic data revealing 30 carbon resonances. The 1H-NMR spectrum (Table 1) of compound 3 exhibited signals of six methyls and an olefinic proton (δH 5.25, s). Resemblance of its NMR spectroscopic data (Tables 1 and 2) with those of 3β,7β,15β-trihydroxy-11,23-dioxolanost-8,16-dien-26-oic acid [16] suggested that their chemical structures were similar. The main difference was a methylol group at δC 66.2 (C-28) in compound 3 instead of a methyl in 3β,7β,15β-trihydroxy-11,23-dioxolanost-8,16-dien-26-oic acid, indicating that compound 3 was derived from the latter with an additional hydroxyl group attached to C-28. This was further confirmed by the HMBC correlation of H-29 (δH 0.72, s) with C-28. The stereo-configuration of compound 3 with a lanostane skeleton was confirmed by ROESY experiments. The β-orientations of 3-OH and 7-OH were determined by cross-peaks of H-3/H-5, H-7/H-5 and H-5/H-28 and the α-orientation of 15-OH was deduced by a H-15/H-18 cross-peak in the ROESY experiment. Accordingly, the structure of compound 3 was identified as 3β,7β,15α,28-tetrahydroxy-11,23-dioxy-lanost-8,16-dien-26-oic acid.

The inhibitory activities of compounds 1–3 against AChE were tested using a spectrophotometric method [19,20]. The results showed that these compounds possessed low percentage inhibition (<10%) at the concentration of 100 μM, compared to the tacrine control, indicating no significant inhibitory activities against AChE. In addition, these isolates were evaluated for antibacterial activity against Staphylococcus aureus, as well as cytotoxic activity against six tumour cells (K-562/HL-60/SMCC-7721/A-549/MCF-7/SW-480) according to the methods described previously [4,21], but they also showed no significant bioactivities.

3. Experimental Section

3.1. General Information

The NMR spectra were measured on an AV-500 spectrometer (Bruker, Bremen, Germany), using tetramethylsilane as internal standard. ESIMS spectra was recorded on an API Qstar Pulsar mass spectrometer (Bruker, Bremen, Germany) and HREIMS was measured with an Autospec Premier mass spectrometer (Waters, Milford, MA, USA). The IR spectra were obtained on a 380 FT-IR instrument (Thermo, Pittsburgh, PA, USA) using KBr pellets. UV spectra were measured on a UV-2550 spectrometer (Shimadzu, Kyoto, Japan). Optical rotations were recorded using a Autopol III polarimeter (Rudolph, Hackettstown, NJ, USA). Column chromatography (CC) was performed with silica gel (Marine Chemical Industry Factory, Qingdao, China), Sephadex LH-20 (Merck, Darmstadt, Germany) and RP-18 (Fuji Silysia Chemical Ltd, United States, 20–45 μm). TLC was performed with silica gel GF254 (Marine Chemical Industry Factory). Biological assay: ELISA Reader (ELx800, Bio-TeK, Winooski,
VT, USA); Acetylthiocholine iodide, AChE, 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) and tacrine (Aldrich 99%) were all bought from Sigma (Santa Clara, CA, USA).

3.2. Fungal Material

Fruiting bodies of G. tropicum were collected in Lingshui County, Hainan Province, China (May, 2011), and identified by Prof. Xing-Liang Wu of Hainan University. A voucher specimen (No. 2011LZ01) is deposited at the Institute of Tropical Bioscience and Biotechnology, Chinese Academy of Tropical Agricultural Sciences.

3.3. Extraction and Isolation

Dried and powdered fruiting bodies of G. tropicum (6.5 kg) were extracted with 95% EtOH (3 L) at room temperature three times for 4 h each time. The combined extracts were concentrated and suspended in H2O followed by successive partitioning with EtOAc and n-BuOH, respectively. The n-BuOH extract (32.0 g) was separated by silica gel CC under reduced pressure using a solvent gradient of CHCl3-CH3OH (30:1→0:1, v/v) to afford five fractions (Fr1-Fr5). Fraction 4 (7.4 g) was separated by Rp-18 CC with MeOH-H2O (30:70→0:100, v/v) to give six subfractions 4a–4f. Subfraction 4c (1.8 g) was repeatedly subjected to silica gel CC eluted with CHCl3-EtOAc (1:1) and Sephadex LH-20 (CHCl3-MeOH 1:1) to yield 2 (8.0 mg) and 3 (4.2 mg).

3.4. Ganotropec Acid (1)

White power; [α]27D +20.0° (c 0.2, MeOH); UV (MeOH) λmax (log ε) 254 (2.19), 213 (0.56), 204 (0.66); IR (KBr) νmax cm−1 3743, 3442, 1768, 1652, 1514, 1461, 1389, 1056, 921; for 1H- and 13C-NMR spectroscopic data, see Tables 1 and 2; positive ESI-MS m/z [M+Na]+ 539 (100); HREIMS (m/z 516.3095 [M]+, calcd. 516.3087 for C30H44O7).

3.5. 3β,7β,15α,24-Tetrahydroxy-11,23-dioxo-lanost-8-en-26-oic Acid (2)

Yellow oil; [α]27D +35.0° (c 0.2, MeOH); UV (MeOH) λmax (log ε) 253 (2.24), 201 (2.69); IR (KBr) νmax cm−1 3734, 3473, 2973, 1701, 1684, 1541, 1457, 1396, 1062, 992, 669; for 1H- and 13C-NMR spectroscopic data, see Tables 1 and 2; positive ESI-MS m/z [M+Na]+ 557 (100); HREIMS (m/z 534.3202 [M]+, calcd. 534.3193 for C30H46O8).

3.6. 3β,7β,15α,28-Tetrahydroxy-11,23-dioxo-lanost-8,16-dien-26-oic Acid (3)

Yellow oil; [α]27D +15.0° (c 0.2, MeOH); UV (MeOH) λmax (log ε) 255 (2.67), 205 (3.35); IR (KBr) νmax cm−1 3730, 2926, 1734, 1652, 1541, 1457, 1396, 873, 669; for 1H and 13C NMR spectroscopic data, see Tables 1 and 2; positive ESI-MS m/z [M+Na]+ 555 (100); HREIMS (m/z 532.3030 [M]+, calcd. 532.3036 for C30H44O8).
3.7. Bioassay of AChE Inhibitory Activity

AChE inhibitory activity of the three compounds was assayed by the spectrophotometric method developed by Ellman [19,20]. Acetylthiocholine iodide was used as substrate in the assay. \( \text{Na}_2\text{HPO}_4 \) (94.7 mL, 0.1 M) and \( \text{NaH}_2\text{PO}_4 \) (5.3 mL, 0.1 M) were mixed to prepare phosphate buffer (PB, pH 8.0). Compounds were dissolved in DMSO (2% in PB). The reaction mixture contained PB (110 μL), test compound solution (10 μL, 2000 μM) and acetyl cholinesterase solution (40 μL, 0.1 U/mL), which were mixed and incubated for 20 min (30 °C). The reaction was initiated by the addition of DTNB (20 μL, 6.25 mM) and acetylthiocholine iodide (20 μL, 6.25 mM). The hydrolysis of acetylthiocholine was monitored at 405 nm every 30 s. Tacrine was used as positive control. All reactions were performed in triplicate. The percentage inhibition was calculated as follows: \% age inhibition = \((E - S) / E \times 100\) (E is activity of the enzyme without test compound and S is the activity of enzyme with test compound).

4. Conclusions

The present study of the mushroom \( G. \ tropicum \) led to the isolation of three new lanostanoid triterpenes: ganotropic acid (1), \( 3\beta,7\beta,15\alpha,24\)-tetrahydroxy-11,23-dioxo-lanost-8-en-26-oic acid (2) and \( 3\beta,7\beta,15\alpha,28\)-tetrahydroxy-11,23-dioxo-lanost-8,16-dien-26-oic acid (3). Ganotropic acid possessed two oxygenic five-membered rings system in the side chain of lanostane skeleton. The evaluation on activities of these new compounds against AChE showed no significant inhibitory activity.

Acknowledgments

This work was financially supported by the Special Fund for Agro-scientific Research in the Public Interest (201303117), the National Support Science and Technology Subject (2013BAI11B04), Fundamental Scientific Research Funds for CATAS [ITBB110301, ITBB140401] and The Major Technology Project of Hainan (ZDZX2013008-4, ZDZX2013023-1). The authors are grateful to the members of the analytical group of Institute of Tropical Bioscience and Biotechnology, Chinese Academy of Tropical Agricultural Sciences for the spectral measurements.

Author Contributions

The contributions of the respective authors are as follows: S.S. Zhang performed isolation, structure elucidation and the bioassay test of the constituents as well as preparing the manuscript. Y.G. Wang contributed to providing the fungal material. Q.Y. Ma and S.Z. Huang contributed to checking and confirming all of the procedures of the isolation and structural identification. L.L. Hu contributed to the UV and IR spectra measurements. H.F. Dai contributed to the interpretation of the NMR spectra and revision of this manuscript. This study was performed based on the planning of Y.X. Zhao and Z.F. Yu, the corresponding authors.

Conflicts of Interest

The authors declare no conflict of interest.
Supplementary Materials

Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/20/02/3281/s1.

References

1. Paterson, R.R.M. *Ganoderma*-A therapeutic fungal biofactory. *Phytochemistry* **2006**, *67*, 1985–2001.
2. Zhao, D.S.; Zhao, W.Y. Study on ganoderma acid in the treatment of rats essential hypertension. *Chin. J. Geriatr.* **2011**, *30*, 858–860.
3. Wang, Y.; Shi, F.Y. The effect of Lingzhi on early nephropathy of diabetic rats. *Chin. J. Diabetes* **2003**, *11*, 327–331.
4. Ma, Q.Y.; Luo, Y.; Zhang, X.J.; Huang, S.Z.; Guo, Z.K.; Dai, H.F.; Zhao, Y.X. Lanostane triterpenoids with cytotoxic activities from the fruiting bodies of *Ganoderma hainanense*. *J. Asian Nat. Prod. Res.* **2013**, *15*, 1214–1219.
5. Peng, X.R.; Liu, J.Q.; Xia, J.J.; Wang, C.F.; Li, X.Y.; Deng, Y.Y.; Bao, N.M.; Zhang, Z.R.; Qiu, M.H. Lanostane triterpenoids from *Ganoderma hainanense* J. D. Zhao. *Phytochemistry* **2014**, in press.
6. Peng, X.R.; Liu, J.Q.; Han, Z.H.; Yuan, X.X.; Luo, H.R.; Qiu, M.H. Protective effects of triterpenoids from *Ganoderma resinaceum* on H2O2-induced toxicity in HepG2 cells. *Food Chem.* **2013**, *141*, 920–926.
7. Liu, L.Y.; Chen, H.; Liu, C.; Wang, H.Q.; Kang, J.; Li,Y.; Chen, R.Y. Triterpenoids of *Ganoderma theaeocolum* and their hepatoprotective activities. *Fitoterapia* **2014**, *98*, 254–259.
8. Thang, T.D.; Kuo, P.C.; Hwang, T.L.; Yang, M.L.; Ngoc, N.T.B.; Han, T.T.N.; Lin, C.W.; Wu, T.S. Triterpenoids and steroids from *Ganoderma mastoporum* and their inhibitory effects on superoxide anion generation and elastase release. *Molecules* **2013**, *18*, 14285–14292.
9. Tung, N.T.; Cuong, T.D.; Hung, T.M.; Lee, J.H.; Woo, M.H.; Choi, J.S.; Kim, J.; Ryu, S.H.; Min, B.S. Inhibitory effect on NO production of triterpenes from the fruiting bodies of *Ganoderma lucidum*. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 1428–1432.
10. Lin, K.W.; Chen, Y.T.; Yang, S.C.; Wei, B.L.; Hung, C.F. Xanthine oxidase inhibitory lanostanoids from *Ganoderma tsugae*. *Fitoterapia* **2013**, *89*, 231–238.
11. Wu, X.L.; Mao, X.L.; Tuli, G.E.; Song, B.; Li, T.H.; Zhao, Y.X.; Chen, S.L.; Zeng, N.K.; Huang, S.Z.; Wen, T.C.; et al. *Medicinal Fungi of China*; Science Press: Beijing, China, 2013; p. 375.
12. Filho, J.M.B.; Medeiros, K.C.P.; Diniz, F.M.; Batista, L.M.; Filho, P.F.A.; Silva, M.S.; da-Cunha, E.; Almeida, J.S.; Quintans-Junior, L.J. Natural products inhibitors of the enzyme acetylcholinesterase. *Rev. Bras. Farmacogn.* **2006**, *16*, 258–285.
13. John, B.; Sulaiman, C.T.; Sadashiva, C.T.; George, S.; Reddy, V.R.K. *In vitro* screening for acetylcholinesterase inhibition of *Baliosperum montanum, Humboldtia brunonis* Wall. var. *raktapushpa* and *Pittosporum viridulum*. *J. Appl. Pharm. Sci.* **2013**, *3*, 63–65.
14. Ahmad, W.; Ahmad, B.; Ahmad, M.; Iqbal, Z.; Nisar, M. *In vitro* inhibition of acetylcholinesterase, butyrylcholinesterase and lipoxygenase by crude extract of *Myricaria elegans* Royle. *J. Biol. Chem.* **2003**, *11*, 1046–1049.
15. Hu, L.L.; Ma, Q.Y.; Huang, S.Z.; Guo, Z.K.; Ma, H.X.; Guo, J.C.; Dai, H.F.; Zhao, Y.X. Three new lanostanoid triterpenes from the fruiting bodies of *Ganoderma tropicum*. *J. Asian Nat. Prod. Res.* **2013**, *4*, 357–362.

16. Hu, L.L.; Ma, Q.Y.; Huang, S.Z.; Guo, Z.K.; Ma, H.X.; Guo, J.C.; Dai, H.F.; Zhao, Y.X. A new nortriterpenoid from the fruiting bodies of *Ganoderma tropicum*. *Phytochem. Lett.* **2014**, *7*, 11–13.

17. Kikuchi, T.; Kanomi, S.; Kadota, S.; Murai, Y.; Tsubobo, K.; Qgita, Z. Constituents of the fungus *Ganoderma lucidum* (Fr.) Karst. I. Structures of ganoderic acid C2, E, I and K, Lucidenic acid F and related compounds. *Chem. Pharm. Bull.* **1986**, *34*, 3695–3712.

18. O’Neill, J.A.; Gallagher, O.P.; Devine, K.J.; Jones, P.W.; Maguire, A.R. Desmethylabietospiran, a Naturally Occurring Self-Gelation Agent. *J. Nat. Prod.* **2005**, *68*, 125–128.

19. Ellman, G.L.; Courtney, K.D.; Andres, V.J.; Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem. Pharmacol.* **1961**, *7*, 88–95.

20. Zhang, S.S.; Ma, Q.Y.; Zou, X.S.; Dai, H.F.; Huang, S.Z.; Luo, Y.; Yu, Z.F.; Luo, H.R.; Zhao, Y.X. Chemical constituents and their *in vitro* acetylcholinesterase inhibitory activities from the fungus *Amauroderma amoiensis*. *Planta Med.* **2013**, *79*, 87–91.

21. Li, W.; Cai, C.H.; Dong, W.H.; Guo, Z.K.; Wang, H.; Mei, W.L.; Dai, H.F. 2-(2-Phenylethyl) chromone derivatives from Chinese agarwood induced by artificial holing. *Fitoterapia* **2014**, *98*, 117–123.

*Sample Availability*: samples are available from authors.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).